Figure 7
From: Functional polarization of human hepatoma HepaRG cells in response to forskolin
Effects of cAMP/rifampicin on BC formation and hepatic marker expression in HepaRG cells. (a–c) HepaRG cells were either exposed to 0.1% (vol/vol) DMSO (control/CTR) or treated for 72 h by 50 µM FSK, 50 µM rifampicin (Rifa), 100 µM Sp-5,6-DCl-cBIMPS or the combination 50 µM rifampicin/100 µM Sp-5,6-DCl-cBIMPS. (a) Cells were then observed by phase contrast microscopy, allowing to distinguish refractive bright/white BC, indicated by white arrows on phase-contrast microscopic pictures; white bar = 50 µm. (b) BC numbers were next quantified by image analysis, as indicated in Methods. (c) mRNA expression of various hepatic markers was determined by RT-qPCR; data are expressed as fold change comparatively to untreated control cells. Data shown are representative of 4 independent experiments (a) or are the means ± SEM of at least 3 independent assays (b,c). (b,c) *p < 0.05 when compared to control cells.
